GRI Key Statistics, Chart & Performance
The current stock price of GRI is 2.6 USD. In the past month the price decreased by -69.86%. In the past year, price decreased by -98.86%.
GRI Technical Analysis
GRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRI. GRI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GRI Financial Highlights
Over the last trailing twelve months GRI reported a non-GAAP Earnings per Share(EPS) of -78.34. The EPS increased by 98.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -275.12% | ||
| ROE | -660.11% | ||
| Debt/Equity | 0 |
GRI Forecast & Estimates
GRI Ownership
GRI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.88 | 398.83B | ||
| AMGN | AMGEN INC | 15.48 | 182.32B | ||
| GILD | GILEAD SCIENCES INC | 17.49 | 177.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.82 | 118.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.11 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 689.8 | 46.48B | ||
| INSM | INSMED INC | N/A | 33.52B | ||
| NTRA | NATERA INC | N/A | 31.42B | ||
| BIIB | BIOGEN INC | 10.56 | 25.93B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.12 | 20.59B | ||
| INCY | INCYTE CORP | 15.72 | 19.81B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.45B |
Related stock screener links
About GRI
Company Profile
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 3 full-time employees. The company went IPO on 2021-02-10. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Company Info
GRI BIO INC
2223 Avenida De La Playa, Suite 208
La Jolla CALIFORNIA US
Employees: 3
Phone: 16194001171
GRI BIO INC / GRI FAQ
What does GRI BIO INC do?
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 3 full-time employees. The company went IPO on 2021-02-10. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
What is the stock price of GRI BIO INC today?
The current stock price of GRI is 2.6 USD. The price decreased by -9.09% in the last trading session.
What is the dividend status of GRI BIO INC?
GRI does not pay a dividend.
How is the ChartMill rating for GRI BIO INC?
GRI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of GRI stock?
GRI BIO INC (GRI) operates in the Health Care sector and the Biotechnology industry.
What is the next earnings date for GRI stock?
GRI BIO INC (GRI) will report earnings on 2026-03-12.